Annual report
7776.TEDINET S100VGWL
Period2024-01-01 → 2024-12-31
Filed2025-03-26
StandardJapan GAAP
ConsolidatedNo
Data checks13 of 13 passed
Key figures · 92
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥193m | 2024-01-01 → 2024-12-31 | Standalone | Net sales |
| Revenue | ¥190m | 2023-01-01 → 2023-12-31 | Standalone | Net sales |
| Revenue | ¥126m | 2022-01-01 → 2022-12-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥162m | 2021-01-01 → 2021-12-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥199m | 2020-01-01 → 2020-12-31d | Standalone | Net sales (5-year summary) |
| Operating income | −¥846m | 2024-01-01 → 2024-12-31 | Standalone | Operating income |
| Operating income | −¥698m | 2023-01-01 → 2023-12-31 | Standalone | Operating income |
| Ordinary income | −¥848m | 2024-01-01 → 2024-12-31 | Standalone | Ordinary income |
| Ordinary income | −¥710m | 2023-01-01 → 2023-12-31 | Standalone | Ordinary income |
| Ordinary income | −¥754m | 2022-01-01 → 2022-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥887m | 2021-01-01 → 2021-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥866m | 2021-01-01 → 2021-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥745m | 2020-01-01 → 2020-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥729m | 2020-01-01 → 2020-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | −¥858m | 2024-01-01 → 2024-12-31 | Standalone | Income before income taxes |
| Profit before tax | −¥846m | 2023-01-01 → 2023-12-31 | Standalone | Income before income taxes |
| Net income (owners) | −¥915m | 2021-01-01 → 2021-12-31d | Standalone | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥784m | 2020-01-01 → 2020-12-31d | Standalone | Profit loss attributable to owners of parent (5-year summary) |
| Net income | −¥860m | 2024-01-01 → 2024-12-31 | Standalone | Profit loss |
| Net income | −¥847m | 2023-01-01 → 2023-12-31 | Standalone | Profit loss |
| Net income | −¥760m | 2022-01-01 → 2022-12-31d | Standalone | Net income loss (5-year summary) |
| Net income | −¥913m | 2021-01-01 → 2021-12-31d | Standalone | Net income loss (5-year summary) |
| Net income | −¥768m | 2020-01-01 → 2020-12-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥2.4bn | at 2024-12-31 | Standalone | Assets |
| Total assets | ¥2.5bn | at 2023-12-31 | Standalone | Assets |
| Total assets | ¥1.5bn | at 2022-12-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.4bn | at 2021-12-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.4bn | at 2021-12-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.8bn | at 2020-12-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.8bn | at 2020-12-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥270m | at 2024-12-31 | Standalone | Liabilities |
| Total liabilities | ¥301m | at 2023-12-31 | Standalone | Liabilities |
| Net assets / equity | ¥2.2bn | at 2024-12-31 | Standalone | Net assets |
| Net assets / equity | ¥2.2bn | at 2023-12-31 | Standalone | Net assets |
| Net assets / equity | ¥1.2bn | at 2022-12-31d | Standalone | Net assets |
| Net assets / equity | ¥1.0bn | at 2021-12-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥1.0bn | at 2021-12-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥1.5bn | at 2020-12-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥1.6bn | at 2020-12-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥2.1bn | at 2024-12-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥2.2bn | at 2023-12-31 | Standalone | Cash and deposits |
| Cash & equivalents | ¥2.1bn | at 2024-12-31 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥2.2bn | at 2023-12-31 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥1.1bn | at 2022-12-31d | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥931m | at 2021-12-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥1.5bn | at 2020-12-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Operating cash flow | −¥866m | 2024-01-01 → 2024-12-31 | Standalone | Net cash provided by used in operating activities |
| Operating cash flow | −¥779m | 2023-01-01 → 2023-12-31 | Standalone | Net cash provided by used in operating activities |
| Operating cash flow | −¥718m | 2022-01-01 → 2022-12-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥817m | 2021-01-01 → 2021-12-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥701m | 2020-01-01 → 2020-12-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥18m | 2024-01-01 → 2024-12-31 | Standalone | Net cash provided by used in investment activities |
| Investing cash flow | ¥56m | 2023-01-01 → 2023-12-31 | Standalone | Net cash provided by used in investment activities |
| Investing cash flow | ¥62m | 2022-01-01 → 2022-12-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥110m | 2021-01-01 → 2021-12-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥13m | 2020-01-01 → 2020-12-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥855m | 2024-01-01 → 2024-12-31 | Standalone | Net cash provided by used in financing activities |
| Financing cash flow | ¥1.8bn | 2023-01-01 → 2023-12-31 | Standalone | Net cash provided by used in financing activities |
| Financing cash flow | ¥882m | 2022-01-01 → 2022-12-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥397m | 2021-01-01 → 2021-12-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥1.1bn | 2020-01-01 → 2020-12-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥-25.72 | 2024-01-01 → 2024-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-29.43 | 2023-01-01 → 2023-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-36.31 | 2022-01-01 → 2022-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-53.18 | 2021-01-01 → 2021-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-53.08 | 2021-01-01 → 2021-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-55.31 | 2020-01-01 → 2020-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-54.19 | 2020-01-01 → 2020-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥62.1 | at 2024-12-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥68.08 | at 2023-12-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥47.26 | at 2022-12-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥56.44 | at 2021-12-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥57.43 | at 2021-12-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥93.85 | at 2020-12-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥95.7 | at 2020-12-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 88.5% | at 2024-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 86.9% | at 2023-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 74.8% | at 2022-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 72.0% | at 2021-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 72.4% | at 2021-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 83.2% | at 2020-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 83.5% | at 2020-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| Shares issued | 34,666,419 | at 2024-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 31,459,019 | at 2023-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 24,422,619 | at 2022-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 17,759,419 | at 2021-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 16,008,319 | at 2020-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 38 | at 2024-12-31 | Standalone | Number of employees |
| Employees | 35 | at 2023-12-31 | Standalone | Number of employees |
| Employees | 30 | at 2022-12-31d | Standalone | Number of employees |
| Employees | 44 | at 2021-12-31d | Standalone | Number of employees |
| Employees | 40 | at 2020-12-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 38
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2024-01-01 → 2024-12-31 | ¥16m |
| Reconciling Itemsreconciling | segment assets | at 2024-12-31 | ¥2.2bn |
| Reconciling Itemsreconciling | segment profit | 2024-01-01 → 2024-12-31 | −¥230m |
| Cell Sheet Regenerative Medicinereportable segment | employees | at 2024-12-31 | 22 pure |
| Cell Sheet Regenerative Medicinereportable segment | revenue | 2024-01-01 → 2024-12-31 | ¥1m |
| Cell Sheet Regenerative Medicinereportable segment | revenue external | 2024-01-01 → 2024-12-31 | ¥1m |
| Cell Sheet Regenerative Medicinereportable segment | segment assets | at 2024-12-31 | ¥70m |
| Cell Sheet Regenerative Medicinereportable segment | segment profit | 2024-01-01 → 2024-12-31 | −¥596m |
| Laboratory Consumables And Equipmentreportable segment | capex | 2024-01-01 → 2024-12-31 | ¥2m |
| Laboratory Consumables And Equipmentreportable segment | employees | at 2024-12-31 | 11 pure |
| Laboratory Consumables And Equipmentreportable segment | revenue | 2024-01-01 → 2024-12-31 | ¥192m |
| Laboratory Consumables And Equipmentreportable segment | revenue external | 2024-01-01 → 2024-12-31 | ¥192m |
| Laboratory Consumables And Equipmentreportable segment | segment assets | at 2024-12-31 | ¥121m |
| Laboratory Consumables And Equipmentreportable segment | segment profit | 2024-01-01 → 2024-12-31 | −¥21m |
| —segment total | capex | 2024-01-01 → 2024-12-31 | ¥2m |
| —segment total | revenue | 2024-01-01 → 2024-12-31 | ¥193m |
| —segment total | revenue external | 2024-01-01 → 2024-12-31 | ¥193m |
| —segment total | segment assets | at 2024-12-31 | ¥191m |
| —segment total | segment profit | 2024-01-01 → 2024-12-31 | −¥616m |
| Reconciling Itemsreconciling | capex | 2023-01-01 → 2023-12-31 | ¥21m |
| Reconciling Itemsreconciling | segment assets | at 2023-12-31 | ¥2.3bn |
| Reconciling Itemsreconciling | segment profit | 2023-01-01 → 2023-12-31 | −¥197m |
| Cell Sheet Regenerative Medicinereportable segment | revenue | 2023-01-01 → 2023-12-31 | ¥8m |
| Cell Sheet Regenerative Medicinereportable segment | revenue external | 2023-01-01 → 2023-12-31 | ¥8m |
| Cell Sheet Regenerative Medicinereportable segment | segment assets | at 2023-12-31 | ¥65m |
| Cell Sheet Regenerative Medicinereportable segment | segment profit | 2023-01-01 → 2023-12-31 | −¥469m |
| Laboratory Consumables And Equipmentreportable segment | capex | 2023-01-01 → 2023-12-31 | ¥770,000 |
| Laboratory Consumables And Equipmentreportable segment | depreciation | 2023-01-01 → 2023-12-31 | ¥8m |
| Laboratory Consumables And Equipmentreportable segment | revenue | 2023-01-01 → 2023-12-31 | ¥182m |
| Laboratory Consumables And Equipmentreportable segment | revenue external | 2023-01-01 → 2023-12-31 | ¥182m |
| Laboratory Consumables And Equipmentreportable segment | segment assets | at 2023-12-31 | ¥133m |
| Laboratory Consumables And Equipmentreportable segment | segment profit | 2023-01-01 → 2023-12-31 | −¥32m |
| —segment total | capex | 2023-01-01 → 2023-12-31 | ¥770,000 |
| —segment total | depreciation | 2023-01-01 → 2023-12-31 | ¥8m |
| —segment total | revenue | 2023-01-01 → 2023-12-31 | ¥190m |
| —segment total | revenue external | 2023-01-01 → 2023-12-31 | ¥190m |
| —segment total | segment assets | at 2023-12-31 | ¥198m |
| —segment total | segment profit | 2023-01-01 → 2023-12-31 | −¥501m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 991
| Item | Context | Value | Unit |
|---|---|---|---|
| Interim dividend paid per share (5-year summary) | Prior2YearDuration_NonConsolidatedMember | － | |
| Interim dividend paid per share (5-year summary) | Prior1YearDuration_NonConsolidatedMember | － | |
| Interim dividend paid per share (5-year summary) | CurrentYearDuration_NonConsolidatedMember | － | |
| Basic earnings loss per share (5-year summary) | Prior4YearDuration_NonConsolidatedMember | -54.19 | |
| Basic earnings loss per share (5-year summary) | Prior3YearDuration_NonConsolidatedMember | -53.08 | |
| Basic earnings loss per share (5-year summary) | Prior2YearDuration_NonConsolidatedMember | -36.31 | |
| Basic earnings loss per share (5-year summary) | Prior1YearDuration_NonConsolidatedMember | -29.43 | |
| Basic earnings loss per share (5-year summary) | CurrentYearDuration_NonConsolidatedMember | -25.72 | |
| Diluted earnings per share (5-year summary) | Prior4YearDuration_NonConsolidatedMember | － | |
| Diluted earnings per share (5-year summary) | Prior3YearDuration_NonConsolidatedMember | － | |
| Diluted earnings per share (5-year summary) | Prior2YearDuration_NonConsolidatedMember | － | |
| Diluted earnings per share (5-year summary) | Prior1YearDuration_NonConsolidatedMember | － | |
| Diluted earnings per share (5-year summary) | CurrentYearDuration_NonConsolidatedMember | － | |
| Equity to asset ratio (5-year summary) | Prior4YearInstant_NonConsolidatedMember | 0.835 | |
| Equity to asset ratio (5-year summary) | Prior3YearInstant_NonConsolidatedMember | 0.724 | |
| Equity to asset ratio (5-year summary) | Prior2YearInstant_NonConsolidatedMember | 0.748 | |
| Equity to asset ratio (5-year summary) | Prior1YearInstant_NonConsolidatedMember | 0.869 | |
| Equity to asset ratio (5-year summary) | CurrentYearInstant_NonConsolidatedMember | 0.885 | |
| Rate of return on equity (5-year summary) | Prior4YearDuration_NonConsolidatedMember | － | |
| Rate of return on equity (5-year summary) | Prior3YearDuration_NonConsolidatedMember | － | |
| Rate of return on equity (5-year summary) | Prior2YearDuration_NonConsolidatedMember | － | |
| Rate of return on equity (5-year summary) | Prior1YearDuration_NonConsolidatedMember | － | |
| Rate of return on equity (5-year summary) | CurrentYearDuration_NonConsolidatedMember | － | |
| Price earnings ratio (5-year summary) | Prior4YearDuration_NonConsolidatedMember | － | |
| Price earnings ratio (5-year summary) | Prior3YearDuration_NonConsolidatedMember | － | |
| Price earnings ratio (5-year summary) | Prior2YearDuration_NonConsolidatedMember | － | |
| Price earnings ratio (5-year summary) | Prior1YearDuration_NonConsolidatedMember | － | |
| Price earnings ratio (5-year summary) | CurrentYearDuration_NonConsolidatedMember | － | |
| Payout ratio (5-year summary) | Prior4YearDuration_NonConsolidatedMember | － | |
| Payout ratio (5-year summary) | Prior3YearDuration_NonConsolidatedMember | － | |
| Payout ratio (5-year summary) | Prior2YearDuration_NonConsolidatedMember | － | |
| Payout ratio (5-year summary) | Prior1YearDuration_NonConsolidatedMember | － | |
| Payout ratio (5-year summary) | CurrentYearDuration_NonConsolidatedMember | － | |
| Net cash provided by used in operating activities (5-year summary) | Prior4YearDuration_NonConsolidatedMember | － | JPY |
| Net cash provided by used in operating activities (5-year summary) | Prior3YearDuration_NonConsolidatedMember | － | JPY |
| Net cash provided by used in operating activities (5-year summary) | Prior2YearDuration_NonConsolidatedMember | -718006000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | Prior1YearDuration_NonConsolidatedMember | -779435000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | CurrentYearDuration_NonConsolidatedMember | -866104000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior4YearDuration_NonConsolidatedMember | － | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior3YearDuration_NonConsolidatedMember | － | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior2YearDuration_NonConsolidatedMember | 61728000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior1YearDuration_NonConsolidatedMember | 56315000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | CurrentYearDuration_NonConsolidatedMember | -18367000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior4YearDuration_NonConsolidatedMember | － | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior3YearDuration_NonConsolidatedMember | － | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior2YearDuration_NonConsolidatedMember | 881814000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior1YearDuration_NonConsolidatedMember | 1814201000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | CurrentYearDuration_NonConsolidatedMember | 855479000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior4YearInstant_NonConsolidatedMember | － | JPY |
| Cash and cash equivalents (5-year summary) | Prior3YearInstant_NonConsolidatedMember | － | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 13 of 13 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |